NUCC-390 dihydrochloride, a novel and selective CXCR4 receptor agonist, effectively induces the internalization of CXCR4 receptors and acts antagonistically to AMD3100 [1]. This small-molecule compound has demonstrated the ability to facilitate functional nerve recovery following neurodegeneration in vivo [2].